title: The effects of simultaneous hyperlipemia-hyperglycemia on the resistance arteries, myocardium and kidney glomeruli.
abstract: The experimental model of Golden Syrian hamster subjected to concomitant hyperlipemia (diet-induced) and diabetes (by streptozotocin injection) for 24 weeks is characterised by the prevalence of micro- and macroangiopathies. We have used the hyperlipemic-diabetic (HD) hamsters to investigate: a) whether there is an alteration in the reactivity of the resistance arteries (mean internal diameter: 210-250 microm), b) if present, which are the structural and biochemical changes that accompany the functional modifications, and c) to examine the pathomorphological changes induced by the association of hyperlipemia and diabetes on vital organs such as myocardium and kidney glomeruli. To these aims, biochemical assays of plasma components, light- and electronmicroscopy, myographic, morphometric and spectrofluorimetric techniques were used. The mesenteric resistance arteries of HD hamsters exhibited (as compared to similar arteries in normals) a decreased contractile response to noradrenaline (1.86+/-0.35 vs. 2.43+/-0.21), and an impeded endothelium dependent relaxation to acetylcholine (approximately 61.40% vs. approximately 79.80%). The association of hyperlipemia with diabetes induced changes in morphology of the resistance arteries consisting in approximately 10% increase of the intima plus media cross-sectional area, approximately 20% decrease of the vascular lumen area, and approximately 2.85 fold augmentation of the wall to lumen ratio. The resistance arteries exhibited structural modifications of the endothelium (up to 8 copies of Weibel-Palade bodies/endothelial cell), and smooth muscle cells (secretory phenotype), and in the vessels media small calcification cores appeared embedded in a hyperplasic extracellular matrix. The vascular mesenteric bed of the HD hamsters contained approximately 2.30 and approximately 1.30 fold increased concentrations of AGE-collagen and pentosidine, respectively, above the normal values. The HD hamsters displayed also modifications that may be dependent on or may lead to an increase in blood pressure, such as: a) approximately 2 fold increase in the activity of serum angiotensin converting enzyme; b) approximately 4.8 fold enhancement of erythrocytes fragility (as a measure of the oxidative stress); c) left ventricular hypertrophy associated with a progressive disarray of cardiomyocyte contractile fibers, interruptions of the Z bands, and accumulation of collagen-rich extracellular matrix indicative of interstitial fibrosis; d) the kidney glomerular capillaries appeared partially or totally collapsed, with a thickened basement membrane which appeared polymorphic, and in some locations made up of successive layers connected by fine bridges and intercalated nodules; in addition, an increase (approximately 1.50 fold) of the mesangial volume was indicative of glomerulosclerosis.
authors.affiliation: Institute of Cellular Biology and Pathology Nicolac Simionescu, Bucharest, Romania.
authors.forename: G
authors.initials: G
authors.lastname: Costache
authors.forename: D
authors.initials: D
authors.lastname: Popov
authors.forename: A
authors.initials: A
authors.lastname: Georgescu
authors.forename: M
authors.initials: M
authors.lastname: Cenuse
authors.forename: V V
authors.initials: VV
authors.lastname: Jinga
authors.forename: M
authors.initials: M
authors.lastname: Simionescu
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000032:analysis; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary; D003094:Collagen / Q000032:analysis; D006224:Cricetinae; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D004912:Erythrocytes / Q000502:physiology; D005920:Glomerular Mesangium / Q000473:pathology* / Q000648:ultrastructure; D017127:Glycation End Products, Advanced / Q000032:analysis; D006949:Hyperlipidemias / Q000150:complications / Q000473:pathology* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D008239:Lysine / Q000031:analogs & derivatives / Q000032:analysis; D008297:Male; D008638:Mesenteric Arteries / Q000473:pathology / Q000503:physiopathology* / Q000648:ultrastructure; D008647:Mesocricetus; D009206:Myocardium / Q000473:pathology; D009638:Norepinephrine / Q000494:pharmacology; D009996:Osmotic Fragility; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D014655:Vascular Resistance / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D002791:Cholesterol, Dietary; D017127:Glycation End Products, Advanced; D003094:Collagen; D001120:Arginine; D002784:Cholesterol; C062187:pentosidine; D007703:Peptidyl-Dipeptidase A; D008239:Lysine; D000109:Acetylcholine; D009638:Norepinephrine